ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2: Immunization, Part 2 – Immunization of Special Populations
and Part 4 – Biological Products

Part 2 - Immunization of Special Populations

Individuals at High Risk for Vaccine Preventable Diseases (Overview)

Individuals at High Risk for Vaccine Preventable Diseases

- Table 1: Vaccines Recommended for Immunocompromised Clients: Removed the term ‘allogeneic’ from the content preceding the table.
- Table 1: “Hepatitis C (chronic)” has been revised to “Hepatitis C (anti-HCV positive)”.
- Table 2: Vaccines Recommended for Individuals with Other Health Conditions: A check mark was added to indicate that pneumococcal vaccines are recommended for persons with neurologic disorders.

Please remove page numbers: 1-3 dated January 2017
Please add new page numbers: 1-3 dated August 2018

Immunocompromised Individuals (General Overview)

Immunization with Inactivated and Live Vaccines

- A link to the Referral Form for Live Attenuated Influenza Vaccination has been added to this page.

Please remove page number: 1 dated June 2018
Please add new page number: 1 dated August 2018
Referral Forms

**Referral Form for Live Attenuated Influenza Vaccination**

- A referral form for LAIV has been created specifically for pediatric oncology clients, including autologous HSCT who are at least 12 months post treatment when LAIV may be considered.

Please add new page number: 1 dated August 2018

**Specific Immunocompromising Conditions**

**Immunization of Pediatric Oncology Clients**

- Content related to PCV13 has been revised to indicate that one dose of PCV 13 should be provided to those 5-18 years of age.
- Updated content related to history of varicella or herpes zoster and receipt of varicella vaccine.
- Content related to LAIV has been revised to indicate that the vaccine may be considered 12 or more months post-treatment.
- The option for LAIV referral was added to the Personalized Schedule Worksheet for Immunization of Pediatric (those under 18 years of age) Oncology Clients who have Completed Treatment, Including Autologous HSCT.

Please remove page numbers: 1-5 dated February 2017
Please add new page numbers: 1-5 dated August 2018

**Approval for Immunization of Pediatric (those under 18 years of age) Oncology and HSCT Clients Who Have Completed Treatment**

- A link to the LAIV referral form has been added to the live vaccine section of the form for pediatric oncology patients who have completed therapy, including autologous HSCT.

Please remove page number: 1 dated February 2016
Please add new page number: 1 dated August 2018

Please also remove the Table of Contents for Part 2 – Immunization of Special Populations dated April 24, 2018 and replace with the enclosed updated Table of Contents dated August 2018.
Part 4 – Biological Products

Influenza Vaccines

2018/19 Seasonal Influenza Vaccines

• Influenza pages for the 2018/19 season have been revised. Eligibility criteria for publicly funded influenza vaccine remain the same as for the previous season.
• Revisions to the influenza pages include:
  o The vaccine strains contained in the 2018/19 influenza vaccines.
  o Added “Eligibility” to the title for the 2018/19 Seasonal Influenza Vaccines page.
  o The “Intended Use of Influenza Vaccines” table has been revised to include INFLUVAC® which is indicated for those “18 years of age and older” and can be provided to those “3 years of age and older” if a quadrivalent product is unavailable. AGRIFLU® and FLUZONE® QUADRIVALENT have been removed from the table. A link to the updated Question & Answer Document related to FLUZONE® High-Dose is also included.
  o CONTRAINDICATIONS have been revised on all influenza vaccine biological products pages to include individuals receiving immunotherapy for cancer using checkpoint inhibitors.
  o Footnote A has been added to CONTRAINDICATIONS on the FLUMIST® QUADRIVALENT page to indicate that LAIV may be considered for pediatric oncology clients, including autologous HSCT, who are 12 or more months post-treatment.
  o A biological products page has been created for INFLUVAC® for the 2018/19 influenza season. This product is thimerosal-free.

Please remove the following pages:

• 2017/18 Seasonal Influenza Vaccines: page 1 dated August 2017
• Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2016
• Intended Use of Influenza Vaccines: page 1 dated September 2017
• FLUMIST® QUADRIVALENT: pages 1-3 dated August 2017
• FLULAVAL® TETRA: pages 1 & 2 dated August 2017
• FLUZONE® QUADRIVALENT: pages 1 & 2 dated September 2017
• FLUVIRAL®: pages 1 & 2 dated August 2017
• AGRIFLU®: pages 1 & 2 dated August 2017

Please add the following pages:

• 2018/19 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2018
• Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2018
• Intended Use of Influenza Vaccines: page 1 dated August 2018
• FLUMIST® QUADRIVALENT: pages 1-3 dated August 2018
• FLULAVAL® TETRA: pages 1 & 2 dated August 2018
• FLUVIRAL®: pages 1 & 2 dated August 2018
• INFLUVAC®: pages 1 & 2 dated August 2018
Pneumococcal Vaccines

Pneumococcal Conjugate Vaccine

Prevnar® 13

- INDICATIONS and DOSES AND SCHEDULE for children 5-18 years of age (inclusive) have been revised to include malignant neoplasm (including leukemia and lymphoma).
- The dosing for children 5-18 years of age with asplenia has been revised from 2 doses to 1 dose to align with the Canadian Immunization Guide.
- The content related to the recommended interval between PCV13 and PPV23 vaccine doses depending on which product was given first has been moved to footnote B which is associated with DOSES AND SCHEDULE.

Please remove page numbers: 1-3 dated March 2015
Please add new page numbers: 1-3 dated August 2018

Please also remove the Table of Contents for Part 4 – Biological Products dated April 24, 2018 and replace with the enclosed updated Table of Contents dated August 2018.

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: christine.halpert@bccdc.ca) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

Dr. Mark Tyndall
Executive Medical Director
BC Centre for Disease Control, and
Deputy Provincial Health Officer

BC Ministry of Health, Population & Public Health Division:
Craig Thompson
Director, Immunization

Wendy Trotter
Executive Director,
Public Health Services